| Retinal Vein Occlusion |
ACTRN12617001487303: Intravitreal Aflibercept for the Treatment of Treatment Resistant Macular Oedema secondary to Retinal Vein Occlusions |
|
|
| Recruiting | 4 | 50 | | | A/Prof Andrew Chang, Bayer Australia Limited | macular oedema secondary to retinal vein occlusion | | | | |
ChiCTR-IPR-16009191: Clinical Efficacy of Intravitreal Conbercept for the Treatment Macular Edema secondary to Branch Retinal Vein Occlusion |
|
|
| Recruiting | 4 | 60 | | conbercept ;Lucentis | Shangdong Provincial Hospital; Shangdong Provincial Hospital, Shandong Nature Science Foundation | retina branch vein occlusion | | | | |
ChiCTR-TRC-10000997: Periocular combined to different dosage Triamcinolone Acetonide intravitreal injection treatment macular edema associated with Retinal Vein Occlusion |
|
|
| Completed | 4 | 117 | | intravitreal injection 4mg Triamcinolone Acetonide ;intravitreal injection 8mg Triamcinolone Acetonide ;intravitreal injection 16mg Triamcinolone Acetonid | XI'an 4th Hospital, Affiliated Guangren Hospital, School of Medicine, Xi'an Jiaotong University; Beijing TongRen Hospital, XI’an No.4 Hospital | macular edema associated with Retinal Vein Occlusion | | | | |
2013-004656-38: Assessment of the suitability of serum VEGF level as diagnostic factor in macula edema under therapy with Lucentis® (ranibizumab) Bewertung der Eignung des Serum VEGF Spiegels als diagnostischer Faktor bei einem Makulaödem unter Therapie mit Lucentis® (Ranibizumab) |
|
|
| Ongoing | 4 | 30 | Europe | Injection, Lucentis Injektionslösung | Prof. Dr. Karl-Heinz Emmerich, Novartis Pharma GmbH | Central retinal vein occlusionRetinal vein occlusion, Occlusion of a vein of the retina, Diseases [C] - Eye Diseases [C11] | | | | |
2014-002790-11: Evaluation of additional peripheral panretinal LASER-treatment on recurrences of macular edema due to CRVO undergoing anti-VEGF treatment with ranibizumab Evaluierung eines „Treat-and-Extend“ Schemas bei Patienten mit retinalem Venenverschluss mit und ohne Laserphotokoagulation von ischämischen Netzhautarealen |
|
|
| Ongoing | 4 | 60 | Europe | Solution for injection, Lucentis | Ludwig-Maximilians Universität München, Novartis | Makulaödem nach retinalem Venenverschluss (CRVO), Auftreten einer Schwellung (Ödem) der Netzhaut nach dem Verschluss des ableitenden Gefäßes und nachfolgender Flüssigkeitsansammlung im Gewebe des Auges, Diseases [C] - Eye Diseases [C11] | | | | |
2012-000765-20: Silmän sisäisten lääkeainepistosten aikaan saama hermoston uudelleen muokaantuvuus Silmän sisäisten lääkeainepistosten aikaan saama hermoston uudelleen muokaantuvuus |
|
|
| Ongoing | 4 | 40 | Europe | Bevacizumab, RO4876646/F02, Concentrate for solution for infusion, Avastin | Kuopion yliopistollinen sairaala/silmätautien poliklinikka, Kuopion yliopistollinen sairaala | Wet age-related macular degeneration, diabetic macular edema, central retinal vein occlusion, Wet age-related macular degeneration, diabetic macular edema, central retinal vein occlusion, Body processes [G] - Ocular Physiological Phenomena [G14] | | | | |
2011-000425-72: Treatment of macular edema secondary to central or branch vein occlusion by dexamethazone intravitreal injection |
|
|
| Ongoing | 4 | 15 | Europe | OZURDEX, OZURDEX | IRCCS- FONDAZIONE G.B. BIETTI PER LO STUDIO E LA RICERCA IN OFTALMOLOGIA-ONLUS | macular edema seconday to central or branch retinal vein occlusion | | | | |
2014-000975-21: Study to evaluate the effectiveness of aflibercept in patients with macular edema secondary to central retinal vein occlusion. Estudio para evaluar la eficacia de aflibercept en pacientes con edema macular secundario a oclusión de la vena central de la retina. |
|
|
| Ongoing | 4 | 50 | Europe | Eylea, Eylea, Eylea, Eylea | Fundación Retinaplus +, Bayer | Macular edema secondary to central retinal vein occlusion. Edema macular secundario a oclusión de la vena central de la retina. | | | | |
| Completed | 4 | 51 | NA | EYLEA 2 MG in 0.05 ML Injection | University of Athens | Retinal Vein Occlusion, Vascular Occlusive Disease | 12/20 | 03/24 | | |
ChiCTR-IPR-16009197: Compound anisodine injection auxiliary treatment of branch retinal vein occlusion macular edema, multicenter clinical study |
|
|
| Recruiting | 4 | 600 | | Vitreous injection of VEGF drugs + temporal artery by subcutaneous injection of compound anisodine injection ;Vitreous injection of VEGF drugs | Affiliated to the Capital University of Medical Sciences, Beijing Tongren Hospital; Affiliated to the Capital University of Medical Sciences, Beijing Tongren Hospital, Beijing zizhu pharmaceutical co., LTD | Branch retinal vein occlusion with macular edema | | | | |
2016-001660-10: Antibody treatment in retinal vein occulsion and the influence on oxygen and blood supply |
|
|
| Ongoing | 4 | 30 | Europe | aflibercept, SUB26987, Solution and suspension for suspension for injection in pre-filled syringe, Eylea 40mg/ml | Universitätsklinik für Augenheilkunde und Optometrie, Univ Klinik für Augenheilkunde und Optometrie | retinal vein occlusion, retinal vein occlusion, Diseases [C] - Eye Diseases [C11] | | | | |
ChiCTR1800018245: Intravitreal Injection of Conbercept for Macular Edema due to Branch Retinal Vein Occlusion: the Efficacy Analysis of Early versus Late |
|
|
| Not yet recruiting | 4 | 40 | | intravitreal Conbercept injection ;intravitreal Conbercept injection | Affiliated Hospital of Qingdao University; Affiliated Hospital of Qingdao University, Affiliated Hospital of Qingdao University | Branch Retinal Vein Occlusion | | | | |
ChiCTR2000033146: A Multicenter, Randomized, Double Blind, Controlled Trial for Zhixue Quyu Mingmu Tablets and Compound Xue-shuan-tong Capsule in the Treatment of Retinal Vein Occlusion Patients with Blood Stasis and Yin Deficiency Syndrome |
|
|
| Completed | 4 | 311 | | Zhixue Quyu Mingmu tablet ;Compound Xueshuantong capsule | Guang'anmen Hospital, Chinese Academy of traditional Chinese Medicine; Guang'anmen Hospital, Chinese Academy of traditional Chinese Medicine, Shanxi momeide Qihe Pharmaceutical Co., Ltd | Retinal vein occlusion | | | | |
ChiCTR1800014289: A randomized, double blind, controlled trials for assessing the efficacy of 0.5 mg ranibizumab only in subject with macular laser combined due to diabetic branch retinal vein occlusion |
|
|
| Recruiting | 4 | 80 | | razorumab combined with macular laser photocoagulation ;razorumab alone | Beijing Hospital; Beijing Hospital, Beijing Hospital | Branch vein occlusion macular edema | | | | |
ChiCTR-OIC-16009509: Clinical study of intravitreal ranibizumab as early treatment for macular edema result by retinal vein occlusion |
|
|
| Not yet recruiting | 4 | 100 | | intravitreal ranibizumab | The Second Xiangya Hospital of Central South University; Department of Ophthalmology of The Second Xiangya Hospital, Central South University, raise independently | retinal vein occlusion | | | | |
ChiCTR-IPR-17010568: The Randomized Double-blind Controlled Clinical Trial of Combination of Intravitreal Ranibizumab With or Without Macular Laser Photocoagulation for Macular Edema Secondary to Branch Retinal Vein Occlusion |
|
|
| Recruiting | 4 | 64 | | macular laser ;no | Beijing Hospital; Beijing Hospital, Beijing Hospital | Branch retinal vein occlusion | | | | |
| Not yet recruiting | 4 | 100 | | Intravitreal injection of conbercept combined with posterior sub-tenon injection of triamcinolone acetonide ;Intravitreal injection of conbercept | China-Japan Friendship Hospital; China-Japan Friendship Hospital, China-Japan Friendship Hospital | Central retinal occlusion | | | | |
2020-005449-18: Spontaneous retinal artery pulses as a prognostic determinant of central retinal vein occlusions in patients with and without intravitreal aflibercept injections Pulsations artérielles rétiniennes spontanées (PARS) en tant que déterminant pronostique des occlusions de la veine centrale de la rétine (OVCR) chez les patients traités ou non par injections intravitréennes d’aflibercept |
|
|
| Not yet recruiting | 4 | 60 | Europe | Solution for injection, Eylea 40 mg/mL, solution injectable en seringue préremplie | Hôpital Fondation A. de Rothschild / Service de recherche clinique, Bayer Healthcare | Central retinal vein occlusions Occlusions de la veine centrale de la rétine (OVCR), Central retinal vein occlusions Occlusions de la veine centrale de la rétine (OVCR), Diseases [C] - Eye Diseases [C11] | | | | |
ChiCTR2000038086: A prospective randomized controlled trial for comparing 1+prn and 3+prn regimen in the treatment of macular edema secondary to branch retinal vein occlusion |
|
|
| Recruiting | 4 | 72 | | Patients were treated with one injection of intravitreal ranibizumab (IVR) and further IVR injections were administered as needed. ;Patients were treated with three consecutive monthly injections of IVR and further IVR injections were administered as needed. | Eye & ENT Hospital of Fudan University; EYE & ENT hospital of FUDAN UNIVERSITY, Beijing Novartis Pharma Co., Ltd. | branch retinal vein occlusion | | | | |
NCT03709745: Eylea and Lucentis for Macular Edema in Branch Retinal Vein Occlusion |
|
|
| Recruiting | 4 | 110 | Europe | Aflibercept Injection [Eylea], Eylea, Ranibizumab Injection [Lucentis], Lucentis | St. Erik Eye Hospital | Branch Retinal Vein Occlusion With Macular Edema | 11/21 | 08/22 | | |
NCT05282420: Ranibizumab Versus Aflibercept for CRVO in Young Patients. |
|
|
| Recruiting | 4 | 40 | RoW | intravitreal injection of Ranibizumab, intravitreal injection of Aflipercept, Ranibizumab, Aflibercept | Qena Faculty of medicine, South Valley University | Non-Ischemic Central Retinal Vein Occlusion With Macular Edema | 04/22 | 05/22 | | |
| Recruiting | 4 | 2323 | | Ranibizumab | Zhongshan Ophthalmic Center, Sun Yat-sen University; Zhongshan Ophthalmic Center, Novartis Beijing | Age-Related Macular Degeneration/Diabetic Macular Edema/Macular Edema secondary to Retinal Vein Occlusion | | | | |
| Completed | 4 | 124 | US | Refresh Plus Preservative-free Lubricant Eye Drops | University of Iowa | Diabetic Retinopathy With Macular Edema of Both Eyes (Diagnosis), Central Retinal Vein Occlusion With Macular Edema, Exudative Age-Related Macular Degeneration, Unspecified Eye, Cystoid Macular Edema, Ocular Surface Disease, Dry Eye Sensation, Eye Pain | 07/22 | 07/22 | | |
JQMMT+RA, NCT06234514: Manage Macular Cystoid Edema With Retinal Vein Obstruction Using Traditional Chinese Medicine and Ranibizumab |
|
|
| Recruiting | 4 | 100 | RoW | Jueling Mingmu decoction, intravitreal injections of 0.5mg ranibizumab, 0.5mg ranibizumab | Dongyang People's Hospital | Macular Cystoid Edema | 12/24 | 12/24 | | |
DETeR, NCT04563299: Effect on Pain and Inflammation With DEXTENZA Treatment in Patients Undergoing Intravitreal Anti-VEGF Injections |
|
|
| Terminated | 4 | 10 | US | Dextenza 0.4Mg Ophthalmic Insert, Prednisolone Acetate | Retina Vitreous Associates of Florida, Ocular Therapeutix, Inc. | Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion | 02/23 | 02/23 | | |
ChiCTR2200058266: Optical coherence tomography (OCTA) observed signs of moving suspended scattering particles (SSPiM) in RVO-ME and their clinical significance |
|
|
| Not yet recruiting | 4 | | | Anti-VEGF therapy ;Anti-VEGF therapy | Dalian NO.3 People's Hospital; Dalian NO.3 People's Hospital, self-funded | retinal vein occlusion (RVO) | | | | |
ACTRN12615001094561: The combination treatment of laser bypass (chorioretinal venous anastomosis) and Lucentis for the treatment of macula oedema (swelling at the back of the eye) that has occurred as a result of a central retinal vein occlusion, compared to the published results of Lucentis treatment only. |
|
|
| Active, not recruiting | 4 | 100 | | | Lions Eye Institute, Lions Eye Institute | Maucula oedema secondary to central retinal vein occlusion. | | | | |
ChiCTR2100046387: efficacy of conbercept combined dexamethasone intravitreal implants for the treatment of cystoid macular edema secondary to retinal vein occlusion |
|
|
| Recruiting | 4 | 80 | | Joint injection ;Anti-VEGF therapy | Tianjin Medical University Eye Hospital; Tianjin Medical University Eye Hospital, Beijing Bethune Public Welfare Foundation | retinal vein occlusion | | | | |
NCT04707625: Vascular Endothelial Growth Factor (VEGF) Levels in Retinal Vein Occlusion (RVO) During Anti-VEGF Treatment |
|
|
| Terminated | 4 | 17 | US | Aflibercept Ophthalmic, Eylea | Wake Forest University Health Sciences | Retinal Vein Occlusion | 12/23 | 12/23 | | |
| Recruiting | 4 | 168 | Canada | Intravitreal ranibizumab | Unity Health Toronto | Age Related Macular Degeneration, Diabetic Macular Edema, Macular Edema, Retinal Vein Occlusion | 02/24 | 02/24 | | |
| Recruiting | 4 | 168 | Canada | Intravitreal aflibercept, Eylea | Unity Health Toronto | Age Related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion, Macular Edema | 02/24 | 02/24 | | |
ChiCTR2300069732: Study on the pathological mechanism of macular edema caused by retinal vein occlusion and related factors affecting treatment prognosis by MLC combined with aqueous humor cytokine detection |
|
|
| Not yet recruiting | 4 | 60 | | Intravitreal injection of Aflibercept ;Intravitreal injection of Ozurdex | Qingdao Eye Hospital of Shandong First Medical University ; Qingdao Eye Hospital of Shandong First Medical University, Qingdao Eye Hospital introduced doctoral research funds | Retinal vein occlusion | | | | |
| Recruiting | 3 | 22 | | | Royal Adelaide Hospital, Royal Adelaide Hospital | Branch Vein Retinal Occlusion | | | | |
2014-000272-26: A Multicentre Phase III Double-masked Randomised Controlled Non-Inferiority Trial comparing the clinical and cost effectiveness of intravitreal therapy with ranibizumab (Lucentis) vs aflibercept (Eylea) vs bevacizumab (Avastin) for Macular Oedema (MO) due to Central Retinal Vein Occlusion (CRVO). |
|
|
| Ongoing | 3 | 459 | Europe | Aflibercept, Bevacizumab, Lucentis, EMA/CHMP/299413/2012, EU/1/04/300/001, Solution for injection, Concentrate for solution for injection, Eylea, Avastin, Lucentis | Moorfields Eye Hospital NHS Foundation Trust, NIHR HTA CET | Macular Oedema due to Central Retinal Vein Occlusion (CRVO)., Swelling of the centre of the retina, the light detecting layer at the back of the eye, due to blockage of a blood vessel that usually drains blood out of this layer., Diseases [C] - Eye Diseases [C11] | | | | |
2006-005468-25: A randomized study comparing the safety and efficacy of ranibizumab (Lucentis ®) to sham in patients with macular edema secondary to central retinal vein occlusion (CRVO). |
|
|
| Ongoing | 3 | 32 | Europe | Lucentis, RFB002, | Retinaklinikken Aleris | Macular edema secondary to central retinal vein occlusion (CRVO) | | | | |
2006-005450-71: INTRAVITREAL RANIBIZUMAB THERAPY FOR MACULA EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION (RAVO) |
|
|
| Ongoing | 3 | 60 | Europe | Lucentis, RFB002, Lucentis, Lucentis | Augenklinik der LMU München | Macula edema resulting from central retinal vein occlusion in the eye | | | | |
2009-017782-30: Treatment of macular edema due to central retinal vein occlusion with ranibizumab (Lucentis®). |
|
|
| Ongoing | 3 | 20 | Europe | not applicable, Lucentis 10 mg/ml Injektionslösung, Lucentis 10 mg/ml Injektionslösung | Medizinische Universität Graz, Universitäts-Augenklinik | This case-series is designed to evaluate the safety and efficacy of intravitreal ranibizumab (Lucentis®) in the treatment of macular edema due to central retinal vein occlusion. | | | | |
2009-017735-18: Etude prospective, contrôlée, randomisée du traitement de l’occlusion sévère de la veine centrale de la rétine à sa phase précoce par injection intra-vitréenne de Bevacizumab |
|
|
| Ongoing | 3 | 50 | Europe | Bevacizumab, avastin, avastin | CHRU Montpellier - Direction de la Recherche | retinal vein occlusion | | | | |
2020-000681-42: Long-term need of the drug ranibizumab applied as injection into the eye with or without early targeted peripheral laser photocoagulation of the retina for treatment of macular edema due to central retinal vein occlusion Langzeitbedarf des Medikaments Ranibizumab als Injektion ins Auge mit oder ohne frühzeitige gezielte periphere Laser-Photokoagulation der Netzhaut zur Behandlung des Makulaödems infolge eines Zentralvenenverschlusses |
|
|
| Not yet recruiting | 3 | 110 | Europe | Ranibizumab, Injection, Lucentis | Justus-Liebig University Gießen, BMBF | Macular edema due to central retinal vein occlusion Makulaödem infolge eines Zentralvenenverschlusses, Macular edema due to central retinal vein occlusion Makulaödem infolge eines Zentralvenenverschlusses der Netzhaut, Diseases [C] - Eye Diseases [C11] | | | | |
ChiCTR2100053499: A Prospective, Randomized, Double-Masked, Active Comparator-Controlled, Multi-Center, Two-Arm, Phase III Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal Aflibercept in Participants with Visual Impairment Due to Treatment-Naive Macular Edema Secondary to Retinal Vein Occlusion (RVO) |
|
|
| Suspended | 3 | 170 | | Intravitreal injection of KSI-301 (5mg) ;Intravitreal injection of aflibercept 2mg | Kodiak Sciences China Inc.; Beijing Tongren Hospital Affiliated to Capital Medical University, self-funded | Macular Edema Secondary to Retinal Vein occlusion | | | | |
ChiCTR2000040087: A 12-month clinical study of conbercept combined with Intravitreal Dexamethasone (DEX) Implant in the treatment of macular edema secondary to central retinal vein occlusion |
|
|
| Recruiting | 3 | 20 | | conbercept combined with Ozurdex ;conbercept | Department of Ophthalmology, Central Theater Command General Hospital,; Central Theater Command General Hospital of PLA, Self-raised funds | Central retinal vein occlusion | | | | |
BEACON, NCT04592419 / 2020-001061-37: A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO) |
|
|
| Completed | 3 | 568 | Europe, US, RoW | KSI-301, Aflibercept, Eylea, Sham Procedure | Kodiak Sciences Inc | Macular Edema, Retinal Vein Occlusion | 06/22 | 01/23 | | |
| Completed | 3 | 553 | Europe, Japan, US, RoW | Faricimab, VABYSMO®, faricimab-svoa, RO6867461, RG7716, Aflibercept, Eylea, Sham Procedure | Hoffmann-La Roche, Chugai Pharmaceutical | Macular Edema, Branch Retinal Vein Occlusion | 07/22 | 06/23 | | |
COMINO, NCT04740931 / 2020-000441-13: A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion |
|
|
| Completed | 3 | 729 | Europe, Japan, US, RoW | Faricimab, VABYSMO®, faricimab-svoa, RG7716, RO6867461, Aflibercept, Eylea, Sham Procedure | Hoffmann-La Roche, Chugai Pharmaceutical | Macular Edema, Central Retinal Vein Occlusion, Hemiretinal Vein Occlusion | 08/22 | 07/23 | | |
NORSE SEVEN, NCT05112861: A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders |
|
|
| Active, not recruiting | 3 | 120 | US | bevacizumab, ONS-5010 | Outlook Therapeutics, Inc. | Age-Related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration, BRVO - Branch Retinal Vein Occlusion, Diabetic Macular Edema | 03/25 | 03/25 | | |
QUASAR, NCT05850520: A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion) |
|
|
| Recruiting | 3 | 822 | Europe, Japan, US, RoW | Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose, Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg, Sham, Fluorescein | Bayer, Regeneron Pharmaceuticals | Macular Edema Secondary to Retinal Vein Occlusion | 11/24 | 05/25 | | |
| Recruiting | 3 | 110 | Europe | Ranibizumab Injection, Lucentis, Laser photocoagulation | University of Giessen, University of Leipzig | Central Retinal Vein Occlusion With Macular Edema | 07/25 | 07/25 | | |
NCT05520177: A Phase III Study for 601 Versus Ranibizumab in Patients With Vision Loss |
|
|
| Recruiting | 3 | 350 | RoW | 601 1.25mg, 601, ranibizumab 0.5mg, Lucentis | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Branch Retinal Vein Occlusion | 12/25 | 12/25 | | |
NCT06572553: Evaluation of Therapeutic Efficacy of Faricimab for Clinical AMD, DME, and RVO Patients |
|
|
| Recruiting | 2/3 | 30 | RoW | Faricimab | Second Affiliated Hospital, School of Medicine, Zhejiang University | Age-Related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion | 08/24 | 08/24 | | |
ACTRN12611000300976: Bevacizumab intravitreal injection in the treatment of patients with Central Retinal Vein Occlusion. |
|
|
| Recruiting | 2 | 22 | | | Royal Adelaide Hospital, Royal Adelaide Hospital | Central retinal vein occlusion (CRVO) | | | | |
2012-000165-20: Clinical trial to evaluate the results of intravitreal bevacizumab injections in cases of recurrence of macular edema secondary to retinal vein thrombosis previously treated with ozurdex Ensayo Clínico para evaluar los resultados del tratamiento con inyecciones intravítreas de bevacizumab en los casos de recidiva del edema macular secundario a trombosis de vena de retina que ha sido tratado previamente con ozurdex |
|
|
| Ongoing | 2 | 53 | Europe | Solution for infusion, AVASTIN | Fundación para la Investigación biomédica del Hospital Universitario Ramón y Cajal. Madrid, Concedida ayuda a la investigación clínica independiente 2011.MSPI. EC11-136 | Macular edema secondary to retinal vein occlusion Edema macular secundario a oclusiones venosas de retina, Visual loss due to Macular edema after retinal vein occlusion La pérdida de visión por edema macular debido a trombosis venosa de la retina, Diseases [C] - Eye Diseases [C11] | | | | |
2008-006265-93: A prospective, randomized, masked and controlled trial of intravitreal bevacizumab (Avastin®) for central retinal vein occlusion (CRVO). |
|
|
| Ongoing | 2 | 60 | Europe | Avastin®, Avastin ®, Avastin ® | St Eriks Eye Hospital | Central retinal vein occlusion (CRVO) is a sight-threatening ocular condition without efficient treatment. | | | | |
2012-005439-10: Re-treatment with intravitreal application of ranibizumab guided by morphological macular changes documented by optical coherence tomography (OCT) in patients with macular edema due to branch retinal vein occlusion Wiederbehandlung mit Ranibizumab bei Patienten mit Makulaödem infolge eines Venenastverschlusses nach morphologischen Netzhautveränderungen erhoben mittels optischer Kohärenztomographie (OCT) |
|
|
| Ongoing | 2 | 24 | Europe | Ranibizumab, Lucentis (Ranibizumab), Lucentis (Ranibizumab) | University of Leipzig Ritterstr. 26, 04109 Leipzig, Novartis | macular edema secondary to branch retinal vein occlusion (BRVO) Makulaödem bei Venenastverschluss | | | | |
2005-003288-21: INTRAOCULAR BEVACIZUMAB (AVASTIN™) FOR CENTRAL AND BRANCH RETINAL VEIN OCCLUSION STUDY |
|
|
| Ongoing | 2 | 30 | Europe | Avastin, EU/1/04/300/001-002, AVASTIN, AVASTIN | Dept. of Ophthalmology, Medical University of Vienna | CENTRAL AND BRANCH RETINAL VEIN OCCLUSION | | | | |
2017-001143-12: A Pilot Study for the Evaluation of Minocycline in the Treatment of Central Retinal Vein Occlusions |
|
|
| Not yet recruiting | 2 | 20 | Europe | Minocycline, Capsule, Minocycline | The National Eye Institute, The National Eye Institute | Central Retinal Vein Occlusion, Central Retinal Vein Occlusion, Diseases [C] - Eye Diseases [C11] | | | | |
2017-001179-21: A Pilot Study for the Evaluation of Minocycline in the Treatment of Branch Retinal Vein Occlusions |
|
|
| Not yet recruiting | 2 | 20 | Europe | Minocycline, Capsule, Minocycline | The National Eye Institute, The National Eye Institute | Branch Retinal Vein Occlusion, Branch Retinal Vein Occlusion, Diseases [C] - Eye Diseases [C11] | | | | |
ChiCTR-IIR-17013018: A Multicenter, Randomized, Double blinding, Parallel Group, Placebo-controlled, Phase IIa Trial to explore the Dose-ranging and Evaluate the Efficacy and Safety of Xuesaitong Soft Capsules in the Treatment of Nonischemic Retinal Vein Occlusion with Static Blood Blocking Collaterals TCM zhen |
|
|
| Recruiting | 2 | 108 | | Xuesaitong Soft Capsules ;Xuesaitong Soft Capsules and Xuesaitong Soft Capsules simulants ;Xuesaitong Soft Capsules simulants (placebo) | Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine; Kunming Shenghuo Pharmaceutical Group Co., Ltd., raise independently | Nonischemic Retinal Vein Occlusion (Syndrome of Static Blood Blocking Collaterals) | | | | |
NCT04667910: 601 Versus Ranibizumab in Patients With Central Retinal Vein Occlusion (CRVO) |
|
|
| Not yet recruiting | 2 | 60 | RoW | 601 1.25mg, Drug 601, Ranibizuman 0.5 mg, Lucentis | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Central Retinal Vein Occlusion | 07/22 | 01/23 | | |
NCT04667897: 601 Versus Ranibizumab in Patients With Branch Retinal Vein Occlusion (BRVO) |
|
|
| Not yet recruiting | 2 | 60 | RoW | 601 1.25mg, Drug 601, Ranibizuman 0.5 mg, Lucentis | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Branch Retinal Vein Occlusion | 07/22 | 01/23 | | |
NCT05290948: Comparison of Combined Intravitreal Bevacizumab and Oral Acetazolamide Versus Intravitreal Bevacizumab Alone for the Treatment of Macular Edema Secondary to Retinal Vein Occlusions |
|
|
| Active, not recruiting | 2 | 57 | RoW | intravitreal injection of bevacizumab with acetazolamide tablets, intravitreal injection of bevacizumab | Shahid Beheshti University of Medical Sciences | Macular Edema | 07/22 | 12/22 | | |
NCT05532735: Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Retinal Vein Occlusion |
|
|
| Active, not recruiting | 2 | 16 | US | ANXV | Annexin Pharmaceuticals AB, InFocus Clinical Research | Retinal Vein Occlusion | 07/24 | 07/24 | | |
NCT06176963: A Study to Evaluate the Usability of the SB11 PFS in Subjects With Wet AMD or Macular Oedema Secondary to RVO |
|
|
| Completed | 2 | 34 | Europe | SB11 PFS, Ranibizumab | Samsung Bioepis Co., Ltd. | Neovascular Age-related Macular Degeneration, Macular Edema, Retinal Vein Occlusion | 11/23 | 12/23 | | |
NCT04576689: Safety and Efficacy of IBE-814 Intravitreal (IVT) Implant - A Sustained, Low Dose Dexamethasone Therapy |
|
|
| Completed | 2 | 60 | Canada, RoW | IBE-814 70ug, Low dose, IBE-814 140ug, High dose | Ripple Therapeutics Pty Ltd, Novotech (Australia) Pty Limited | Diabetic Macular Oedema, Retinal Vein Occlusion With Macular Oedema | 04/23 | 03/24 | | |
| Completed | 1/2 | 16 | US | Autologous Bone Marrow CD34+ Stem Cells, Sham Therapy | The Emmes Company, LLC, National Eye Institute (NEI), University of California, Davis | Central Retinal Vein Occlusion | 11/23 | 11/23 | | |
| Unknown status | 1 | | | | Beijing Friendship Hospital, Capital Medical University; None, Beijing Friendship Hospital, Capital Medical University | Diabetic retinopathy, CRVO, AION | | | | |
NCT04120311: Episcleral Dexamethasone for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole |
|
|
| Active, not recruiting | 1 | 2 | US | Episcleral Dexamethasone, Sequestered Transscleral, Controlled-Release Dexamethasone, Sustained Release Transscleral Dexamethasone | Targeted Therapy Technologies, LLC | Macular Edema, Radiation Retinopathy, Branch Retinal Vein Occlusion, Epiretinal Membrane, Central Serous Retinopathy With Pit of Optic Disc, Commotio Retinae, Vitritis | 09/24 | 09/24 | | |
NCT05099094: VEGFA-targeting Gene Therapy to Treat Retinal and Choroidal Neovascularization Diseases |
|
|
| Recruiting | 1 | 18 | RoW | BD311 | Shanghai BDgene Co., Ltd., Eye & ENT Hospital of Fudan University | Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion | 09/23 | 09/23 | | |
NCT01736059: Clinical Trial of Autologous Intravitreal Bone-marrow CD34+ Stem Cells for Retinopathy |
|
|
| Active, not recruiting | 1 | 15 | US | CD34+ bone marrow stem cells intravitreal | University of California, Davis | Non-exudative Age-related Macular Degeneration, Diabetic Retinopathy, Retina Vein Occlusion, Retinitis Pigmentosa, Hereditary Macular Degeneration | 10/25 | 10/25 | | |
NCT04120636: Phase I Study of Episcleral Celecoxib for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole |
|
|
| Active, not recruiting | 1 | 3 | US | Episcleral Celecoxib, Sustained Release Transscleral Celecoxib | Targeted Therapy Technologies, LLC | Macula Edema, Radiation Retinopathy, Branch Retinal Vein Occlusion, Epiretinal Membrane, Central Serous Retinopathy With Pit of Optic Disc, Commotio Retinae, Vitritis | 06/24 | 06/24 | | |
| Recruiting | 1 | 16 | Europe | Annexin A5, Flurescein Angiography | University Medical Center Groningen | Retinal Vein Occlusion | 01/24 | 05/24 | | |
NCT04690608: Suprachoroidal Injection of Triamcinolone Acetonide in Resistant Diabetic Macular Edema, CRVO, Pseudophakic Cystoid Macular Edema and Diabetic Macular Edema Following Pars Plana Vitrectomy |
|
|
| Not yet recruiting | 1 | 100 | RoW | Triamcinolone Acetonide 40Mg/Ml Inj,Susp_#1, 30 gauge syringe with 24 gauge cannula | Tanta University | Retinal Edema | 12/24 | 02/25 | | |
NCT04008121: Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium |
|
|
| Not yet recruiting | 1 | 10 | US | Fluorescein sodium and Zeiss FF450 fundus camera, MB-102 and Zeiss FF450 fundus camera, Fluorescein sodium and commercially available optical angiography imaging system, MB-102 and commercially available optical angiography imaging system | MediBeacon | Retinopathy, Retinal Vein Occlusion, Diabetic Retinopathy, Macular Degeneration | 12/24 | 12/24 | | |
ChiCTR2200061397: Evaluation of the therapeutic effect of integrated traditional Chinese and western medicine on macular edema of central retinal vein occlusion |
|
|
| Not yet recruiting | 1 | 62 | | Intravitreal injection of rizumab injection combined with Quji Tongluo decoction ;Intravitreal injection of rizumab injection combined with placebo | Eye hospital of Chinese Academy of Chinese Medical Sciences; Chinese Academy of Chinese Medical Sciences, China Academy of Traditional Chinese Medicine Science and Technology Innovation Major Public Relations Project | Retinal vein occlusion-macular edema | | | | |
| Completed | 1 | 60 | | The ranibizumab group, The patients received ranibizumab intravitreal injections in the first three months as the initial treatment. Patients might receive repeat injections during the follow-up in case of the recurrence of macular edema; The recurrence of macular edema is defined as the central macular thickness ≥ 300 um, or the increase of central macular thickness ≥ 50 um from the baseline.; The combination group (ranibizumab combined with dexamethasone intravitreal implant).In the combination group, patients received an intravitreal injection of dexamethasone implant after the first injection of ranibizumab at day 15. The recurrence of macular edema is defined as the central macular thickness ≥ 300 um, or the increase of central macular thickness ≥ 50 um from the baseline. | Sanmenxia Eye Hospital; Sanmenxia Eye Hospital, self-funding | macular edeam secondary to retinal vein occlusion | | | | |
ChiCTR2000040201: Study on repairing effect of collateral therapy on macular microvascular injury in branch retinal vein occlusion |
|
|
| Not yet recruiting | N/A | 147 | | Oral Chinese Medicine Quji Tongluo Decoction ;Oral Chinese medicine Quji Tongluo Decoction plus collateral acupuncture treatment ;Intravitreal injection of anti-VEGF drugs | Eye Hospital, China Academy of Chinese Medical Sciences; Eye Hospital, China Academy of Chinese Medical Sciences, Capital clinical characteristic application research project | Branch retinal vein occlusion | | | | |
ChiCTR-TRC-05000661: A Randomized Controlled Trial to Compare the Safety and Efficacy of Intravitreal Triamcinolone Versus Combined Triamcinolone and Grid Laser Versus Observation in the Treatment of Macular Edema Associated With Central Retinal Vein Occlusion |
|
|
| Completed | N/A | 300 | | Treatment of macular edema secondary to CRVO with ivTA without laser 30 months | Nil; Level of the institution：, N/A | Eye Diseases | | | | |
| Recruiting | N/A | 70 | | Nil | The First Affiliated Hospital of Xi’an Jiaotong University; The First Affiliated Hospital, Xi’an Jiaotong University, Provincial funds | age-related macular degeneration, Branch retinal vein occlusion | | | | |
ChiCTR1800018253: The analysis of correlative factors of visual acuity with intravitreal Conbercept injection in macular edema associated with branch retinal vein occlusion |
|
|
| Recruiting | N/A | 35 | | intravitreal Conbercept injection | Qingdao University Affiliated Hospital; Qingdao University Affiliated Hospital, Qingdao University Affiliated Hospital | branch retinal vein occlusion | | | | |
ChiCTR1900022442: Metabolic characterization of human aqueous humor in relation to age related macular degeneration and retinal vein occlusion |
|
|
| Recruiting | N/A | 90 | | intravitreal anti-VEGF injection ;intravitreal anti-VEGF injection ;phacoemulsification+Intraocular lens implantation | Tianjin Eye Hospital; Tianjin Eye Hospital, The National Natural Science Funds (No. 81700849) | Age Related Macular Degeneration；Retinal Vein Occlusion | | | | |
ChiCTR1900023782: Characteristics of retinal oxygen saturation in patients with retinal vein occlusion |
|
|
| Not yet recruiting | N/A | 80 | | No intervention ;No intervention ;No intervention ;No intervention | Chengdu University of Traditional Chinese Medicine; Chengdu University of Traditional Chinese Medicine, Application of MSFRI in theoretical research of Chinese medicine (2013YQ49085904) | Retina | | | | |
ChiCTR1900028003: Conbercept and Triamcinolone Acetonide for Macular Edema Secondary to Retinal Vein Occlusion |
|
|
| Recruiting | N/A | 90 | | intravitreal injection of conbercept/intravitreal injection of triamcinolone acetonide ;intravitreal injection of conbercept/intravitreal injection of triamcinolone acetonide | The second Hospital of Dalian Medical University; The second Hospital of Dalian Medical University, Bethune - Langmu Young and middle-aged ophthalmic research fund (Beijing Bethune Public Welfare Foundation, No.BJ-LM2015009L) | Retinal vein occlusion | | | | |
| Recruiting | N/A | 66 | | Conbercept ;Conbercept & Dex | Qingdao Eye Hospital, Shandong Eye Institute; Qingdao Eye Hospital, Shandong Eye Institute, Ophthalmic Fund of Bethune.Langmu | Central Retina Vein Occlusion | | | | |
NCT06146309: Assessment Of Peri-papillary Retinal Nerve Fiber Layer Thickness In Patients With Unilateral Branch Retinal Vein Occlusion |
|
|
| Completed | N/A | 60 | RoW | aflibercept (2mg/0.05ml) | Al-Azhar University | Branch Retinal Vein Occlusion | 07/22 | 08/22 | | |
ChiCTR1800017818: Optimization of vitreoretinal surgery for branch retinal vein occlusion combined with vitreous hemorrhage |
|
|
| Completed | N/A | 40 | | vitreoretinal surgery combined with anti-VEGF ;Vitreoretinal surgery combined with fan-shape photocoagulation | The Eye Hospital of Wenzhou Medical University; The Eye Hospital of Wenzhou Medical University, Supporting Funds of the The Eye Hospital of Wenzhou Medical University | branch retinal vein occlusion | | | | |
ACTRN12624000463572: Randomised Clinical Trial: Influence of Subconjunctival Anaesthesia Duration on Pain Perception During Intravitreal Injections |
|
|
| Completed | N/A | 240 | | | Jiyeon Kim, Christchurch Public Hospital, Eye clinic | intravitreal injection pain, age-related macular degeneration, retinal vein occlusion, diabetic macular oedema | | | | |
| Completed | N/A | 42 | | na ;na | Sleep and Ventilation Unit. Pneumology Department. Marqués de Valdecilla University Hospital. Cantabria University. Santander. Spain; Department of Internal Medicine. Marqués de Valdecilla University Hospital. Cantabria University. IDIVAL. Santander. Spain., no funding | osas | | | | |
ChiCTR1900021186: Study for the effect of acupuncture points on the original scheme at the normal people and patients with retinal vascular ophthalmopathy features |
|
|
| Not yet recruiting | N/A | 180 | | acupuncture ;acupuncture ;acupuncture ;acupuncture ;acupuncture ;acupuncture | Chengdu University of Traditional Chinese Medicine/Academy of Ophthalmology; Chengdu University of TCM Ineye hospital, 1. National Natural Science Foundation; 2. National Natural Science Foundation Balance Funding Project. | Pathological myopia, retinal vein occlusion, uveitis, retinitis pigmentosa, optic atrophy, age-related macular disease | | | | |
NCT04601688: Branch Retinal Vein Occlusion (BRVO) Treatment With Bevacizumab and Dexamethasone or Bevacizumab Only. |
|
|
| Not yet recruiting | N/A | 100 | RoW | Bevacizumab Ophthalmic and Intravitreal Dexamethasone, Avastin®, Ozurdex®, Bevacizumab Ophthalmic | He Eye Hospital | Branch Retinal Vein Occlusion | 03/21 | 09/21 | | |
NCT04601701: Central Retinal Vein Occlusion (CRVO) Treatment With Bevacizumab and Dexamethasone or Bevacizumab Only. |
|
|
| Recruiting | N/A | 100 | RoW | Bevacizumab Ophthalmic and Intravitreal Dexamethasone., Avastin®, Ozurdex®, Bevacizumab Ophthalmic. | He Eye Hospital | Central Retinal Vein Occlusion | 03/21 | 09/21 | | |
ChiCTR2000036655: Clinical Double-Blind Randomized Controlled Trial of Quji Tongluo Decoction in Intervention of Branch Retinal Vein Occlusion Secondary Macular Edema |
|
|
| Recruiting | N/A | 160 | | Oral Quji Tongluo Granules combined with intravitreal injection of anti-vascular endothelial growth factor ;Oral placebo granules combined with intravitreal injection of anti-vascular endothelial growth factor | Eye Hospital, China Academy of Chinese Medical Sciences; Eye Hospital, China Academy of Chinese Medical Sciences, The Evidence-Based Capacity Building Project of Traditional Chinese Medicine of the State Administration of Traditional Chinese Medicine | Retinal vein occlusion | | | | |
ChiCTR2000041414: The relationship between the occurrence of retinal vein occlusion disease and blood composition |
|
|
| Recruiting | N/A | 120 | | Nil | The First Affiliated Hospital of Suzhou University; The First Affiliated Hospital of Suzhou University, Clinical trial facility Capacity enhancement program of Suzhou Science and Technology Bureau SLT201916 | Retinal vein occlusion | | | | |
ChiCTR2000030625: Clinical observation of Dan-Hong Hua-Yu oral solution in treating retinal vein occlusion |
|
|
| Not yet recruiting | N/A | 66 | | Conventional basic treatment ;Danhong Huayu oral solution | Beijing Hospital of traditional Chinese Medicine Affiliated to Capital Medical University; Beijing Hospital of Traditional Chinese Medicine, TCM evidence-based capacity building project | Retinal vein occlusion | | | | |
NIRVO, NCT04847869: Near-Infrared Light Photobiomodulation Treatment for Retinal Vein Occlusion Macular Oedema |
|
|
| Recruiting | N/A | 14 | RoW | Ellex Integre NIR laser | University of Sydney | Macula Edema, Retinal Vein Occlusion | 12/21 | 07/22 | | |
ChiCTR2100042682: Intravitreal Dexamethasone Implant Versus Intravitreal Ranibizumab Injection for Treatment of Macular Edema Secondary to Retinal Vein Occlusion: a Prospective, Randomized Trial. |
|
|
| Recruiting | N/A | 40 | | Lucentis ;Lucentis and Ozudex | Shandong First Medical University affiliated Qingdao Eye Hospital; Shandong First Medical University affiliated Qingdao Eye Hospital, Allocation of hospital | Macular edema | | | | |
ChiCTR2100046750: Preliminary study on intestinal microflora and metabolomics in retinal vein occlusion |
|
|
| Recruiting | N/A | 40 | | None ;None | West China Hospital, Sichuan University; West China Hospital, Sichuan University, self-funded | retinal vein occlusion | | | | |
NAAVA, NCT04137120: Study to Gather Information on the Safety and Use of Aflibercept Injections Into the Eye for the Treatment of Eye Disorders in Mexican Routine Clinical Practice |
|
|
| Completed | N/A | 73 | RoW | Aflibercept (BAY86-5321, Eylea), Eylea®; Eylia®; Wetlia®; VEGF Trap-Eye | Bayer | Retinal Disease | 08/22 | 02/23 | | |
ChiCTR2000036135: Wide-field OCT angiography guided laser precision therapy for branch retinal vein occlusion (BRVO) |
|
|
| Not yet recruiting | N/A | 50 | | 3+PRN(lucentis）+preventive laser ;3+PRN（lucentis）+on-demanded laser | Eye and ENT hospital of Fudan University; Eye and ENT hospital of Fudan University, Hospital Development Center | Branch Retinal vein occlusion | | | | |
HERMES Study, NCT02880644: Ultra-wide Fluorescein Angiography in Patients With Central Retinal Vein Occlusion Treated by Afilbercept |
|
|
| Completed | N/A | 65 | Europe | | Centre Hospitalier Intercommunal Creteil, Bayer, Association Clinique Thérapeutique Infantile du val de Marne | Retinal Vein Occlusion | 11/22 | 11/22 | | |
ChiCTR2100049861: An open label, randomized control trial on the effect of Xuesaitong soft capsule combined with anti-vascular endothelial growth factor drug (anti-VEGF drug) in the treatment of retinal vein occlusion with macular edema |
|
|
| Not yet recruiting | N/A | 36 | | Anti-vascular endothelial growth factor drugs + basic therapy ;basic therapy | Affiliated Hospital of Yunnan University; Kunming China Resources Holy Fire pharmaceutical Co., LTD, Kunming China Resources Holy Fire pharmaceutical Co., LTD | retinal vein occlusion with macular edema | | | | |
ChiCTR2200061103: Analysis of Visual Acuity Prognostic Factors in Patients with Retinal Vein Occlusion |
|
|
| Recruiting | N/A | 100 | | None | Peking University Third Hospital Yanqing Hospital; eking University Third HospitalYanqing Hospital, Self-financing | Retinal Vein Occlusion | | | | |